BIO3 Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €31.60 |
| 52 Week High | €36.40 |
| 52 Week Low | €29.60 |
| Beta | 0.29 |
| 1 Month Change | -0.63% |
| 3 Month Change | -5.67% |
| 1 Year Change | -11.73% |
| 3 Year Change | 55.67% |
| 5 Year Change | 26.15% |
| Change since IPO | 401.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.9% | -2.1% | 1.7% |
| 1Y | -11.7% | -8.0% | -7.6% |
Return vs Industry: BIO3 underperformed the German Biotechs industry which returned -4.6% over the past year.
Return vs Market: BIO3 underperformed the German Market which returned -8.5% over the past year.
Price Volatility
| BIO3 volatility | |
|---|---|
| BIO3 Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: BIO3 is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BIO3's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,228 | Michael Ramroth | https://www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3 fundamental statistics | |
|---|---|
| Market Cap | €1.46b |
| Earnings (TTM) | -€47.20m |
| Revenue (TTM) | €517.40m |
2.4x
P/S Ratio-26.5x
P/E RatioIs BIO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3 income statement (TTM) | |
|---|---|
| Revenue | €517.40m |
| Cost of Revenue | €394.00m |
| Gross Profit | €123.40m |
| Other Expenses | €170.60m |
| Earnings | -€47.20m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 10, 2023
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 23.85% |
| Net Profit Margin | -9.12% |
| Debt/Equity Ratio | 185.4% |
How did BIO3 perform over the long term?
See historical performance and comparison